Balchem Corp (BCPC): what the price requires
At today's price, Balchem Corp (BCPC) is priced for +20.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/BCPC
Headline
| Field | Value |
|---|---|
| Ticker | BCPC |
| Company | Balchem Corp |
| Current price | $161.37/sh |
| Composition | Product Sales Revenue 100% / Royalty Revenue 0% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 15.4% |
| Operating margin today | 20.1% |
| Margin compression implied | -4.7pp |
| Implied growth | 20.4% |
| Multiple paid | 25x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.8% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.7pp.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +1.85σ |
| cohort percentile (of 76 peers) | 78 |
| sustained it ~5 years at this level | 42% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.66x | 5 | expensive |
| Earnings | 2.64x | 5 | expensive |
| Relative | 1.95x | 5 | expensive |
| Growth | 0.97x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $165.52 | 0.97x | yes | FCF base $0.2B, growth 10% (input: historical growth), terminal g 4.0%, WACC 9.0%, 6yr projection |
| DCF Exit Multiple | Growth | $177.91 | 0.91x | yes | Exit EV/EBITDA: 18.7x / 20.7x / 22.7x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $97.57 | 1.65x | yes | P/E 19.69x (blended: static sector reference 14x + trailing (TTM) 33x), scenarios: 16.4x / 19.7x / 23.0x (bear / base = reference held flat / bull), EV/EBITDA 11.81x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $52.93 | 3.05x | yes | BV/sh $39.81, ROE (TTM) 12.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $60.64 | 2.66x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $139.14 | 1.16x | yes | Rev $1.1B, growth 10% (input: historical growth; tapered), Terminal P/S: 4.1x / 4.9x / 5.7x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $82.63 | 1.95x | yes | EPS $4.87, growth 17% (input: historical EPS growth), PEG=1.94 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $39.75 | 4.06x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.17B × (1−21%) / WACC 9.0% → EPV (no growth) |
| Residual Income | Asset | $62.22 | 2.59x | yes | BV $39.81 + 5yr PV of (ROE (TTM) 12.3% − Kₑ 9.3%) × BV; BV grows 8.0%/yr |
| Graham Number | Asset | $66.04 | 2.44x | yes | √(22.5 × EPS $4.87 × BVPS $39.81) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $58.59 | 2.75x | yes | EBITDA $0.26B × sector EV/EBITDA 8.0x |
| FCF Yield | Earnings | $67.61 | 2.39x | yes | FCF $220.2M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $61.05 | 2.64x | yes | SBC-adj FCF $0.20B (FCF $0.22B − SBC $0.02B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $157.14 | 1.03x | yes | EPS $4.87 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $13.13 | 12.29x | yes | BV $39.81 × (ROIC 3.0% / WACC 9.0%) |
| P/Sales Sector | Relative | $49.13 | 3.28x | yes | Revenue $1.06B × sector P/S 1.5x |
| PEG Fair Value | Relative | $123.95 | 1.30x | yes | EPS $4.87 × (PEG 1.5 × growth 17.0% (input: historical EPS growth)) → PE 25.5x |
| Earnings Yield | Earnings | $52.65 | 3.06x | yes | EPS $4.87 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $71.2m |
| Net debt / NOPAT (after-tax) | -0.42x (net cash) |
| Net debt / operating income (pre-tax) | -0.33x (net cash) |
| Share count CAGR (buyback) | -0.1% |
| Burning cash | no |
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
- Balchem is a specialty-ingredients compounder that has now posted 27 consecutive quarters of year-over-year adjusted-EBITDA growth, with all three segments growing in the first quarter and Human Nutrition and Health, the largest, up 8.3% to $171.6 million.
- The price is the risk: today's level requires operating profit to compound at roughly 22% a year for five years, well above what the company has actually delivered, so the bet is on durability of the premium rather than on the current numbers.
- The balance sheet removes the financial-distress question entirely, with net cash of about $71 million and almost no debt, leaving the debate squarely about growth and multiple rather than solvency.
Bull Case
What the market is paying for Balchem is steadiness, and the company keeps supplying it. The first quarter brought record first-quarter net sales of $270.7 million, up 8.1%, and adjusted EBITDA of $74.3 million, up 12.1%, the twenty-seventh consecutive quarter of year-over-year EBITDA growth. That is the kind of record that does not come from one product cycle; it comes from a portfolio of small, defensible niches in nutrition ingredients that each compound quietly. The 10-K describes the Human Nutrition and Health segment as the core, and in the quarter it grew 8.3% to $171.6 million on double-digit growth in minerals and nutrients tied to consumer health trends.
The breadth is the bull point most screens miss. Animal Nutrition and Health rose 8.6% to $62.2 million, and Specialty Products, the smallest line at $34.7 million, grew 4.4% with record earnings from operations. The 10-K notes that 2025 Animal Nutrition sales rose 7.5%, with average selling prices contributing to the gain, which is pricing power showing up in a segment most investors treat as commodity. Three segments growing together, none dependent on a single customer, no customer accounted for more than 10% of total net sales in 2025, is a diversified earnings stream rather than a one-product story.
The balance sheet lets management compound without distraction. Balchem carries net cash of about $71 million and essentially no debt, so free cash flow, $33.8 million in the quarter, can fund the bolt-on acquisitions that have historically built the portfolio rather than service interest. Operating margin runs above 20%, and return on equity sits in the low teens on a book value that has grown steadily. For a buyer, the bet is that the same playbook, niche ingredients, pricing power, occasional tuck-in deals, keeps running. The record streak says it has not broken yet.
Bear Case
The cleanest way into the bear case is to ask what management does with the cash, because the price assumes the answer keeps being excellent. Balchem generates strong free cash flow and carries net cash, which means the growth the price demands has to come from somewhere: organic expansion in mid-single-digit-growth ingredient markets, or acquisitions priced into a competitive deal market. The 10-K's own segment results, Human Nutrition up 8.3% and Animal Nutrition around 8%, are healthy but not 22%. The gap between what the business grows at and what the price requires has to be closed by capital deployment that works every time, and acquisition-led compounding is exactly where multiples like this one tend to disappoint when a deal underwhelms or integration drags.
The valuation is the structural problem. At today's price the market pays about 26 times company-wide operating income, and only the growth-DCF method reaches that level. Every other family, asset value, earnings power, and peer multiples, lands well below the price; the earnings-power and asset lenses read it as more than double what the static economics support. The implied assumption, roughly 22% operating-profit growth sustained for five years, runs well above the company's own delivered pace, and of comparable fast-growers historically only about 39% sustained that rate even five years. The bet is durability the static frames cannot price, which is another way of saying the margin for error is thin if growth normalizes toward the high single digits the segments actually print.
The operating risks are real even if modest. The 10-K flags raw-material exposure directly: in periods of rapidly increasing raw material prices, we may be unable to pass increases in raw material costs through to our customers due to certain contractual obligations, which can compress the margins the premium depends on. Customer concentration is low on a sales basis, but the filing notes one customer at 14% of receivables, a reminder that the diversification is not total. None of these breaks the business. They simply mean that at 26 times operating income, with the multiple resting on a single valuation family, ordinary disappointments carry outsized price consequences.
Valuation
Today's price is a bet on durability, and the inversion states it plainly: to support the current level, company-wide operating profit has to grow about 22% a year for five years. That is well above what Balchem has actually delivered, and history is not encouraging on persistence, only about 39% of comparable fast-growers held that pace even five years. The price is not crazy, but it is paying in advance for a continuation of the record streak rather than for the trailing numbers.
The method disagreement is unusually one-sided. Of the four families, only the growth-DCF approach reaches the price. Asset value, earnings power, and peer multiples all sit well below it, with the earnings-power and asset lenses reading the price at more than double what the static economics justify. When only the forward-growth family reaches the price and every backward-looking method says expensive, the premium is a moat-and-durability bet the static frames structurally cannot frame. The 26-times operating-income multiple is the compounding story capitalized, not a reflection of current earnings power.
Solvency is the part of the picture that is unambiguously strong, and it changes the shape of the downside. Net cash of about $71 million against essentially no debt means there is no leverage to amplify a stumble; free cash flow of $33.8 million in the quarter funds the bolt-on deals the strategy runs on. The downside here is not financial distress, it is multiple compression. If growth fades toward the high-single-digit pace the segments print, the methods that already say expensive set the gravity, and a richly valued name with a clean balance sheet still re-rates when the durability assumption is questioned. The strength of the balance sheet bounds the loss; it does not defend the multiple.
Catalysts
Balchem's first quarter was a beat-and-extend: net sales of $270.7 million, up 8.1% and a first-quarter record, net earnings of $40.3 million, and adjusted EBITDA of $74.3 million, up 12.1%. The EBITDA figure marked the twenty-seventh consecutive quarter of year-over-year growth, the metric the bull case leans on. Free cash flow was $33.8 million in the quarter.
The segment detail is what moves the fundamental story. Human Nutrition and Health, the largest segment, grew 8.3% to $171.6 million on double-digit growth in minerals and nutrients tied to consumer health demand. Animal Nutrition and Health rose 8.6% to $62.2 million, and Specialty Products grew 4.4% to $34.7 million while posting record earnings from operations. All three lines growing together, with the smallest setting an earnings record, is the diversified-compounder thesis showing up in the print.
The watch item is whether that 8% organic pace can carry a multiple priced for far more, and whether management deploys its net-cash balance sheet into accretive deals as the streak's comparison base gets harder. The next earnings print is the test of both: continued EBITDA growth keeps the streak alive, but the durability of pricing power against the raw-material pressure the filing flags is the variable that decides whether the premium holds.
Peer Cohorts (Per Segment, With Filing Citations)
Human Nutrition & Health (HNH) (reported)
- SXT (Sensient Technologies Corp)
- (no filing in the citation store)
- IFF (INTERNATIONAL FLAVORS & FRAGRANCES INC)
- (no filing in the citation store)
- INGR (INGREDION INCORPORATED)
- (no filing in the citation store)
- IOSP (INNOSPEC INC.)
- (no filing in the citation store)
- NGVT (INGEVITY CORPORATION)
- (no filing in the citation store)
Animal Nutrition & Health (ANH) (reported)
- PAHC (Phibro Animal Health Corporation)
- (no filing in the citation store)
- ELAN (Elanco Animal Health Incorporated)
- (no filing in the citation store)
- ZTS (Zoetis Inc.)
- (no filing in the citation store)
- NEOG (Neogen Corporation)
- (no filing in the citation store)
Specialty Products (SP) (reported)
- NEU (NEWMARKET CORPORATION)
- (no filing in the citation store)
- IOSP (INNOSPEC INC.)
- (no filing in the citation store)
- ECVT (Ecovyst Inc.)
- (no filing in the citation store)
- NGVT (INGEVITY CORPORATION)
- (no filing in the citation store)
- CBT (Cabot Corporation)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Balchem Q1 2026 earnings release, April 30 2026